ALIM vs. ATOS, VERU, LFCR, TRVI, OMER, ZVRA, RIGL, OGI, SKYE, and IVA
Should you be buying Alimera Sciences stock or one of its competitors? The main competitors of Alimera Sciences include Atossa Therapeutics (ATOS), Veru (VERU), Lifecore Biomedical (LFCR), Trevi Therapeutics (TRVI), Omeros (OMER), Zevra Therapeutics (ZVRA), Rigel Pharmaceuticals (RIGL), Organigram (OGI), Skye Bioscience (SKYE), and Inventiva (IVA). These companies are all part of the "pharmaceutical preparations" industry.
Atossa Therapeutics (NASDAQ:ATOS) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment.
Alimera Sciences received 127 more outperform votes than Atossa Therapeutics when rated by MarketBeat users. However, 64.96% of users gave Atossa Therapeutics an outperform vote while only 57.63% of users gave Alimera Sciences an outperform vote.
12.7% of Atossa Therapeutics shares are owned by institutional investors. Comparatively, 99.8% of Alimera Sciences shares are owned by institutional investors. 7.8% of Atossa Therapeutics shares are owned by company insiders. Comparatively, 31.4% of Alimera Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Atossa Therapeutics presently has a consensus target price of $4.50, indicating a potential upside of 171.08%. Alimera Sciences has a consensus target price of $7.50, indicating a potential upside of 105.48%. Given Alimera Sciences' higher possible upside, equities analysts clearly believe Atossa Therapeutics is more favorable than Alimera Sciences.
Alimera Sciences has higher revenue and earnings than Atossa Therapeutics. Atossa Therapeutics is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.
Atossa Therapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
Atossa Therapeutics has a net margin of 0.00% compared to Atossa Therapeutics' net margin of -24.93%. Alimera Sciences' return on equity of -31.01% beat Atossa Therapeutics' return on equity.
In the previous week, Alimera Sciences had 2 more articles in the media than Atossa Therapeutics. MarketBeat recorded 4 mentions for Alimera Sciences and 2 mentions for Atossa Therapeutics. Alimera Sciences' average media sentiment score of 0.97 beat Atossa Therapeutics' score of 0.12 indicating that Atossa Therapeutics is being referred to more favorably in the media.
Summary
Alimera Sciences beats Atossa Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Alimera Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alimera Sciences Competitors List
Related Companies and Tools
